1. Executive Summary
2. Research Methodology
3. Rheumatoid Arthritis
3.1 Overview
3.2 Causes
3.3 Types of RA
4. Rheumatoid Arthritis Diagnosis & Treatment
4.1 Diagnosis
4.2 Treatment
5. Market Analysis
5.1 Market Sizing (Actual & Forecasted)
5.2 Market Share Analysis
5.2.1 Market Share by Molecule Type
5.2.2 Market Share by Distribution Channel
5.2.3 Market Share by Region
6. Rheumatoid Arthritis Therapeutics
6.1 Biopharmaceuticals
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 Biologics
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Drug Type
6.1.3 Biosimilars
6.1.3.1 Market Sizing (Actual & Forecasted)
6.2 Pharmaceuticals
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 NSAIDs
6.2.3 Analgesics
6.2.4 DMARDs
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 Glucocorticoids
7. Regional Analysis
7.1 North America
7.1.1 Market Sizing (Actual & Forecasted)
7.1.2 Market Share by Molecule Type
7.2 Asia Pacific
7.2.1 Market Sizing (Actual & Forecasted)
7.3 Europe
7.3.1 Market Sizing (Actual & Forecasted)
8. Market Dynamics
8.1 Industry Trends & Developments
8.1.1 Preference for Combination Therapies
8.1.2 Growing Demand for Janus Kinase (JAK) inhibitors
8.1.3 Use of Anti-ACPAs for Clinical Diagnosis
8.1.4 FDA Approval of Auto-Injector for RA
8.2 Growth Drivers
8.2.1 Prevalence of Rheumatoid Arthritis
8.2.2 Increasing Geriatric Population
8.2.3 Growing Patient Awareness
8.3 Challenges
8.3.1 Entry of Biosimilars
8.3.2 High Cost of Treatment
8.3.3 Issues related to Insurance & Reimbursement
9. Competitive Landscape
10. Company Profiles
10.1 Abbvie Inc.
10.2 Amgen Inc.
10.3 F. Hoffmann-La Roche AG
10.4 Johnson & Johnson
10.5 Pfizer Inc.